ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Sjögren’s Syndrome"

  • Abstract Number: 0997 • ACR Convergence 2020

    Novel Shared Antibody Specificities in Ro Antibody Negative Sjögren’s Syndrome

    Sherri Longobardi1, Constantin Georgescu2, Christina Lawrence3, Charmaine Moya3, Jonathan Wren4, Judith James5, Kathy Sivils3 and A. Darise Farris6, 1Graduate Program in Biological Sciences, University of Oklahoma Health Sciences Center; Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Genes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Genes & Human Disease Program, Oklahoma Medical Research Foundation, Oklahoma City, 5Oklahoma Medical Research Foundation, Oklahoma City, 6Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City

    Background/Purpose: Sjögren’s syndrome (SS) is a rheumatic autoimmune disease characterized by focal lymphocytic infiltrates in the lacrimal and salivary glands, severe dry mouth and eyes,…
  • Abstract Number: 1409 • ACR Convergence 2020

    Lack of Conventional Acinar Cells in the Salivary Gland Following Anti PD-L1 and anti-PD-1 Immune Checkpoint Inhibitor Therapy

    Sarah Pringle1, Bert van der Vegt1, Xiaoyan Wang1, Nico van Bakelen1, Arjan Vissink1, Frans Kroese2 and Hendrika Bootsma2, 1UMCG, Groningen, 2University Medical Centre Groningen, Groningen, Netherlands

    Background/Purpose: Salivary glands (SGs) can be damaged by immune checkpoint inhibitor (ICI) therapy. In patients with ICI-induced SG dysfunction, 60% progress to fulfill the ACR-EULAR…
  • Abstract Number: 1242 • ACR Convergence 2020

    Transcranial Direct Current Stimulation for Fatigue in Patients with Sjogren’s Syndrome: A Randomized, Double-blind Pilot Study

    Ana Pinto1, Sara Piva2, Alexia Vieira3, Samantha Gomes3, Aline Rocha4, Daniela Tavares3, Marcia Santana3, Cristiane Carlesso5, Adagmar Andriolo3, Fania Santos6, Felipe Fregni7 and Virginia Trevisani3, 1Universidade Federal do Amapa, Sao Paulo, Brazil, 2Department of Physical Therapy, University of Pittsburgh, Pittsburgh, PA, 3Universidade Federal de Sao Paulo, Sao Paulo, Brazil, 4Universidade Federal de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, 5University of Pittsburgh, Pittsburgh, 6Universidade Federal de Sao Paulo, Sao Paulo, Saint Helena, 7Harvard Medical School, Cambridge, MA

    Background/Purpose: Transcranial direct-current stimulation (tDCS) has shown promise to decrease fatigue. However, it has never been examined in primary Sjogren Syndrome (pSS). We aimed to assess…
  • Abstract Number: 1502 • ACR Convergence 2020

    Composite of Relevant Endpoints for Sjögren’s Syndrome (CRESS)

    Suzanne Arends1, Liseth de Wolff2, Jolien van Nimwegen3, Gwenny Verstappen2, Jelle Vehof2, Arjan Vissink4, Neelanjana Ray5, Frans Kroese2 and Hendrika Bootsma2, 1University Medical Centre Groningen and Medical centre Leeuwarden, Groningen, Netherlands, 2University Medical Centre Groningen, Groningen, Netherlands, 3University Medical Center Groningen, Groningen, Netherlands, 4University Medical Centre Groningen, Leek, Netherlands, 5Bristol-Myers Squibb, Lawrenceville

    Background/Purpose: Several recent randomized controlled trials that used the validated ESSDAI as primary endpoint failed, partly explained by relatively large response rates in the placebo…
  • Abstract Number: 1243 • ACR Convergence 2020

    Self-reported Fatigue in Patients with Primary Sjögren’s Syndrome Is Associated with an Objective Decline in Physical Performance and Symptoms of Pain and Depression

    Roeland Prak1, Suzanne Arends2, Greetje van Zuiden1, Frans Kroese1, Hendrika Bootsma1 and Inge Zijdewind1, 1University Medical Centre Groningen, Groningen, Netherlands, 2University Medical Centre Groningen and Medical centre Leeuwarden, Groningen, Netherlands

    Background/Purpose: Fatigue is a major complaint in autoimmune diseases including primary Sjögren’s syndrome (pSS). For many pSS patients, fatigue is their most dominant and disabling…
  • Abstract Number: 1503 • ACR Convergence 2020

    Ultra High‐resolution Ultrasound (UHFUS) of Labial Salivary Glands Might Help to Avoid Unnecessary Lip Biopsy in Patients with Sicca Syndrome

    Chiara Baldini1, Francesco Ferro1, Rossana Izzetti2, Saverio Vitali3, Giacomo Aringhieri3, Silvia Fonzetti4, Marta Mosca1, Valentina Donati5, Stefano Bombardieri1 and Davide Caramella3, 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 2Department of Surgical Pathology, Medicine, Molecular and Critical Area, University of Pisa, Pisa, Italy, Pisa, 3Diagnostic and Interventional Radiology, Department of Translational Research and of New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, Pisa, 4Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, 5Pathology Unit, AOUP, Pisa

    Background/Purpose: Major salivary gland ultrasonography (SGUS) has an established role as a first-line imaging tool in the diagnosis of primary Sjögren’s syndrome (pSS). Nowadays, however,…
  • Abstract Number: 1244 • ACR Convergence 2020

    Clinical Characteristics and Outcomes in Patients with Primary Sjögren’s Syndrome-Associated Interstitial Lung Disease

    Joanna Marco1, Gregory Gardner1 and Nishant Gupta2, 1University of Washington, Seattle, WA, 2University of Cincinnati, Cincinnati

    Background/Purpose: Primary Sjögren’s syndrome (pSS) is a chronic autoimmune exocrinopathy that features interstitial lung disease (ILD) in up to 16% of patients. The clinical characteristics…
  • Abstract Number: 1504 • ACR Convergence 2020

    Four Distinct Symptom-Based Clusters Identified from the Sjӧgren’s Foundation Survey

    Sara McCoy1, Christie Bartels2, Miguel Woodham1, Noah Maerz1, Esen Akpek3, Ian Saldanha4, Matthew Makara5 and Alan Baer6, 1University of Wisconsin, Madison, 2University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI, 3Johns Hopkins University, Baltimore, 4Brown University, Providence, 5Sjogren's Syndrome Foundation, Reston, 6Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Relief of symptoms is a sine qua non for successful drug development in Sjӧgren’s syndrome (SS). However, symptom-based patient experience is understudied, particularly how…
  • Abstract Number: 1245 • ACR Convergence 2020

    Smoking Might Reduce Odds of Sjӧgren’s Syndrome Among Rheumatoid Arthritis Patients

    Sara McCoy1 and Christie Bartels2, 1University of Wisconsin, Madison, 2University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI

    Background/Purpose: Smoking increases the risk of many rheumatic disease, including rheumatoid arthritis (RA). Previous studies have identified that current smoking might reduce the risk of…
  • Abstract Number: 1505 • ACR Convergence 2020

    Antibodies Binding Ro/SSA and Muscarinic 3 Receptor in Sjogren’s Syndrome

    R. Scofield1, Syed Quadri2, Valerie Harris2, Biji Kurien2 and Kristi Keolsch2, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Oklahoma Health Sciences Center, Oklahoma City, OK

    Background/Purpose: Sjögren’s syndrome is characterized by exocrine gland dysfunction and autoantibody production.  Some data suggest autoantibodies binding the muscarinic 3 receptor (M3R) mediate poor function…
  • Abstract Number: 1246 • ACR Convergence 2020

    Sjogren’s Syndrome and Its Risk of Cervical Lesions

    Kelly Corbitt1, Isis Lopez2 and Schartess Culpepper3, 1Jackson Memorial Hospital/University of Miami Internal Medicine Residency Program, Miami, 2Baylor College of Medicine Rheumatology Fellowship Program, Miami, 3University of Miami Hospital System, Miami

    Background/Purpose: Sjogren’s syndrome is chronic inflammatory disease that results in lacrimal and salivary dysfunction and can include extra-glandular manifestations. While it is well established that…
  • Abstract Number: 1506 • ACR Convergence 2020

    Correction of Sjögren’s Syndrome Fluid Secretion Deficits in Salivary Gland Acinar Cells by Aquaporin-1 Gene Transfer

    Paola Perez1, Blake Warner2, Sandra Wainer1, Youngmi Ji1, Thomas Pranzatelli1 and Jay Chiorini1, 1Nidcr, National Institute of Health, Bethesda, MD, 2National Institute of Dental and Craniofacial Research, Bethesda

    Background/Purpose: The hallmark clinical complaints in Sjögren’s syndrome (SS) are dry mouth and dry eyes related to salivary and lacrimal glands dysfunction. Reduced salivation reflects…
  • Abstract Number: 1247 • ACR Convergence 2020

    Features of Childhood Sjogren’s Syndrome: A Literature Review Based Cohort

    Achille Marino1, Micol Romano2, Teresa Giani3, Carla Gaggiano4, Stefania Costi5, Revika Singh6, Jay Mehta7, Scott Lieberman8 and Rolando Cimaz9, 1Department of Pediatrics, Desio Hospital, Milan, 2ASST Gaetano Pini-CTO Institute, Milan, Italy, Milan, Italy, 3AOU Meyer, Florence, Italy, 4Department of Pediatrics, University of Siena, Siena, Italy, Siena, Italy, 5University of Milan, Milan, Italy, Milan, Italy, 6Northwestern University, Evanston, IL, 7Division of Rheumatology, Children's Hospital of Philadelphia, Philadelphia, USA, Philadelphia, PA, 8Department of Pediatrics, University of Iowa, Iowa City, US, Iowa City, IA, 9ASST Gaetano Pini-CTO Institute and Università degli Studi di Milano, Milan, Italy, Milan, Italy

    Background/Purpose: Sjogren’s syndrome (SS) is an autoimmune chronic disease characterized by inflammation of exocrine glands, but it can affect other organs as well.This study aims…
  • Abstract Number: 1611 • ACR Convergence 2020

    Documentation of Pregnancy Counseling in SSA-Positive Patients of Childbearing Potential: A Cross-Sectional Study

    Heinrich-Karl Greenblatt1 and Elena Weinstein1, 1University of Colorado School of Medicine, Aurora, CO

    Background/Purpose: Systemic lupus erythematosus (SLE) and primary Sjogren's Syndrome (SS) are highly associated with anti-SSA (anti-Ro) seropositivity. Anti-SSA autoantibodies may cross the placenta, causing a…
  • Abstract Number: 1248 • ACR Convergence 2020

    Patients Seropositive for La/SSB Without Ro/SSA Differ from Those Displaying La/SSB with Ro/SSA in a Single Center Sjogren’s Cohort

    Rana Mongroo1, Samira Chowdhury2 and Steven Carsons2, 1Mount Sinai South Nassau Hospital, Mineola, NY, 2NYU Winthrop Hospital, Mineola, NY

    Background/Purpose: Sjögren’s disease (SS) is characterized by the presence of antibodies against protein-small RNP complexes designated Ro/SSA and La/SSB. Both are included in the 2002…
  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology